Devyser Diagnostics AB

Devyser Diagnostics maintains a strong liquidity position, with cash and equivalents amounting to 201 million SEK, which is significantly higher than its total liabilities of 121.9 million SEK. The company's current ratio of 4.4 indicates a robust ability to meet short-term obligations. However, the company reported negative operating cash flow of -32.4 million SEK and free cash flow of -26.9 million SEK, reflecting ongoing operational challenges.

Profitability metrics show a mixed picture. The company reported a net loss of 23 million SEK and an operating loss of 23.1 million SEK, with a return on equity of -6.25% and a return on assets of -4.7%. These figures are below the industry median for profitability, indicating that the company is underperforming relative to its peers in terms of generating returns on invested capital and assets.

Geographically, the company's revenue is not disclosed by region, but its operations are primarily based in Sweden. The company's business is concentrated in the healthcare diagnostics segment, with no material diversification into other product lines or markets. This concentration increases exposure to sector-specific risks, such as regulatory changes or shifts in reimbursement policies.

Looking ahead, the company is expected to continue facing financial pressures. The current fiscal year is projected to show a decline in revenue, with no significant growth expected in the next fiscal year. The company's capital expenditures of -38.3 million SEK suggest ongoing investment in infrastructure, but this has not yet translated into positive operating cash flow.

Risk factors include the company's negative net income and operating income, which could impact its ability to sustain operations without additional financing. The risk assessment indicates low dilution risk, but the company's liquidity risk is also rated as low, suggesting that it has sufficient cash reserves to manage near-term obligations. No immediate filing-based dilution or liquidity flags were detected.

Recent events include the publication of analyst price targets, with a mean of 161.33 SEK and a median of 164.00 SEK. Analysts have issued a total of three positive recommendations (1 strong buy and 2 buys), with no holds or negative ratings. These signals suggest a generally optimistic outlook from the investment community, despite the company's current financial performance.

Revenue grew 27.9% CAGR from 2022 to 2026, demonstrating strong top-line expansion momentum.

Analysts project 159.4% upside to a mean price target of 161.33 SEK, signaling strong market confidence.

Cash conversion ratio of 1.41 exceeds the 75th percentile of the biotechnology cohort, highlighting efficient cash management.

The company faces high credit risk, posing a significant threat to financial stability and borrowing costs.

Free cash flow remains deeply negative at -51.5 million SEK in 2026, indicating persistent cash burn.

Net income loss widened to -8.4 million SEK in 2026, reflecting ongoing profitability challenges despite revenue growth.

Debt-to-equity ratio of 0.18 ranks in the bottom quartile of the cohort, suggesting higher leverage risk.

Capital expenditure relative to revenue is in the bottom quartile, potentially limiting future growth capacity.

Revenue kr 61.8M, +12,8% YoY; Operating income +112,7% YoY.

• ▍Revenue kr 61.8M, +12,8% YoY
• ▍Operating income +112,7% YoY
• ▍Net income +113,6% YoY
• ▍Free cash flow +93,3% YoY
• ▍Net margin 4.7%

Revenue kr 72.0M, +12,2% YoY; Operating income +2 485,7% YoY.

• ▍Revenue kr 72.0M, +12,2% YoY
• ▍Operating income +2 485,7% YoY
• ▍Net income +528,1% YoY
• ▍Free cash flow +129,7% YoY
• ▍Net margin 19.0%

Revenue kr 56.4M, +15,8% YoY; Operating income +105,5% YoY.

• ▍Revenue kr 56.4M, +15,8% YoY
• ▍Operating income +105,5% YoY
• ▍Net income +87,9% YoY
• ▍Free cash flow +59,6% YoY
• ▍Net margin -5.0%

Revenue kr 67.4M, +26,7% YoY; Operating income +124,7% YoY.

• ▍Revenue kr 67.4M, +26,7% YoY
• ▍Operating income +124,7% YoY
• ▍Net income +105,7% YoY
• ▍Free cash flow +64,7% YoY
• ▍Net margin 1.9%

Revenue kr 54.8M; Operating income -kr 20.5M.

• ▍Revenue kr 54.8M
• ▍Operating income -kr 20.5M
• ▍Net margin -38.9%

Revenue kr 64.2M; Operating income kr 700.0k.

• ▍Revenue kr 64.2M
• ▍Operating income kr 700.0k
• ▍Net margin -5.0%

Revenue kr 48.7M; Operating income -kr 23.7M.

• ▍Revenue kr 48.7M
• ▍Operating income -kr 23.7M
• ▍Net margin -47.6%

Revenue kr 53.2M; Operating income -kr 23.1M.

• ▍Revenue kr 53.2M
• ▍Operating income -kr 23.1M
• ▍Net margin -43.2%

Revenue kr 250.5M, +15,5% YoY; Operating income +117,3% YoY.

• ▍Revenue kr 250.5M, +15,5% YoY
• ▍Operating income +117,3% YoY
• ▍Net income +86,3% YoY
• ▍Free cash flow +53,5% YoY
• ▍Net margin -3.4%

Revenue kr 216.9M, +28,1% YoY; Operating income +1,0% YoY.

• ▍Revenue kr 216.9M, +28,1% YoY
• ▍Operating income +1,0% YoY
• ▍Net income −14,7% YoY
• ▍Free cash flow −52,7% YoY
• ▍Net margin -28.4%

Revenue kr 169.3M, +33,7% YoY; Operating income −13,4% YoY.

• ▍Revenue kr 169.3M, +33,7% YoY
• ▍Operating income −13,4% YoY
• ▍Net income −16,6% YoY
• ▍Free cash flow −13,7% YoY
• ▍Net margin -31.7%

Revenue kr 126.6M, +35,4% YoY; Operating income −144,9% YoY.

• ▍Revenue kr 126.6M, +35,4% YoY
• ▍Operating income −144,9% YoY
• ▍Net income −121,7% YoY
• ▍Free cash flow −171,3% YoY
• ▍Net margin -36.3%